Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Gastric Cancer
NCT01836120Phase 2Unknown
- Sponsor
- Hebei Cancer Hospital
- Start
- Apr 2013
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of raltitrexed in gastric cancer (GC) (2 arms), sponsored by Hebei Cancer Hospital. Primary endpoint: Progression-free survival at 1 year. Status: unknown.
02
Drugs
raltitrexed
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01836120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01836120.